PTC-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Deterwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER				
DESIGNATED/ELECTED OFFICE (DO/EO/US)	532232000900 U.S. APPLICATION NO. (if known, see 37 CFR 1.5)				
CONCERNING A SUBMISSION UNDER 35 U.S.C. 371	10/531,545				
INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 20 October 2003	PRIORITY DATE CLAIMED  18 October 2002				
TITLE OF INVENTION PROCESSES FOR IDENTIFYING QUADRUPLEX-TARGETED ANTIVIRA	AL MOLECULES				
APPLICANT(S) FOR DO/EO/US	i i i i i i i i i i i i i i i i i i i				
Adam SIDDIQUI-JAIN					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/	-				
1. This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.					
2. x This is a SECOND or SUBSEQUENT submission of items concerning a si					
This is an express request to begin national examination procedures (35 Linclude items (5), (6), (9) and (21) indicated below.	J.S.C. 371(f)). The submission must				
4. The US has been elected (Article 31).					
5. A copy of the International Application as filed (35 U.S.C. 371 (c)(2))					
a. is attached hereto (required only if not communicated by the Internatio	nal Bureau).				
b. has been communicated by the International Bureau.					
c. is not required, as the application was filed in the United States Receiv	ing Office (RO/US).				
6. An English language translation of the International Application as filed (35)	5 U.S.C. 371(c)(2)).				
a. is attached hereto.					
b. has been previously submitted under 35 U.S.C. 154(d)(4).					
7. Amendments to the claims of the International Application under PCT Artic	le 19 (35 U.S.C. 371(c)(3))				
a. are attached hereto (required only if not communicated by the International Bureau).					
b. have been communicated by the International Bureau.					
c. have not been made; however, the time limit for making such amendments has NOT expired.					
d. have not been made and will not be made.					
8. An English language translation of the amendments to the claims under PC	CT Article 19 (35 U.S.C. 371(c)(3)).				
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).					
An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
1. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.					
2. An assignment document for recording. A separate cover sheet in complia	nce with 37 CFR 3.28 and 3.31 is included.				
A preliminary amendment.					
4. An Application Data Sheet under 37 CFR 1.76.					
5. A substitute specification.					
6. A power of attorney and/or change of address letter.					
A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 – 1.825 (1 CDR).					
8. A second copy of the published International Application under 35 U.S.C.	. 154(d)(4).				
9. A second copy of the English language translation of the international app	plication under 35 U.S.C. 154(d)(4).				

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. 10/531,545 PCT/US03/33366		ATTORNEY'S DOCKET NUMBER 532232000900							
20. x Other items or information:  Response To Notice To Comply (10 pages) Statement to Support Filing and Submission (2 pages) Paper copy of Sequence Listing (2 pages) Copy of Notice to Comply (2 pages) Return Receipt Postcard									
The fol	lowing fees h	ave been	submitte	d			CALCULATIO	NS	PTO USEONLY
1 —	•			)		\$300	\$		1 10 OCEONET
22. Examination fee (37 CFR 1.492(c))  If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$				
23. Search fee (37 CFR 1.492(b))  If the written opinion of the ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1)-(4)					\$				
	TOTAL OF 21	22 and 23 =	<b>-</b>				<b>\$</b> 0.	00	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)).  The fee is \$250 for each additional 50 sheets of paper or fraction thereof.				program listing in an					
Total Sheets	Extra Sheets		Number of each additional 50 or fraction thereof (round up to a whole number)						
- 100 =	/50	=				x \$250.00	\$		
Surcharge of \$130 for furnishing any of the search fee, examination fee, or the oath or declaration after the date of commencement of the national stage (37 CFR 1.492(h)).					\$				
CLAIMS	S N	UMBER FIL	ED	NUMBER EXTRA		RATE			
Total clair		-20 = x							
Independent		- 3 =			×	····			
MULTIPLE DEPENDENT CLAIM(S) (if applicable) +									
TOTAL OF ABOVE CALCULATIONS :				/E CALCULATIONS =	\$ 0.0	00			
X Applicant claims small entity status. See 37 CFR 1.27. Fees above are reduced by 1/2.			duced by 1/2.	0.0	00				
SUBTOTAL =			SUBTOTAL =	\$ 0.0	00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$				
TOTAL NATIONAL FEE =			AL NATIONAL FEE =	\$		0.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property \$									
			eng w	тс	ATC	FEES ENCLOSED =	\$		0.00
							Amount to be refunded:	\$	
							Amount to be charged	\$	0.00

PTO-1390 (Rev. 07-2005)
Approved for use through 03/31/2007. OMB 0651-0021
U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

a. A check in the amount of \$	to cover the above fees is enclosed.				
b. Please charge my Deposit Account No. A duplicate copy of this sheet is enclosed.	in the amount of \$	to cover the above fees.			
C X The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 03-1952 .—A duplicate copy of this sheet is enclosed.—					
d. Fees are to be charged to a credit card. WARNIN should not be included on this form. Provide c	IG: Information on this form may become pu				
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed an granted to restore the International Application to pending status.					
	4	•			
SEND ALL CORRESPONDENCE TO:	Brenda	Mallach			
Brenda J. Wallach	SIGNATURE U				
Morrison & Foerster LLP 12531 High Bluff Drive, Suite #100 San Diego, California 92130	Brenda NAME	a J. Wallach			
CUSTOMER NUMBER: 25225	REGISTRATION N	5,193 UMBER			
•					
		į			
		j			
I hereby certify that this correspondence is being deposite US, in an envelope addressed to: MS PCT, Commissions shown below.					
Dated: December 13, 2005 Signature:	Judy al	udy Calem)			

#### CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 783 104 053 US

Date of Deposit: December 13, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Judy Calem

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Adam SIDDIQUI-JAIN

Serial No.:

10/531,545

Filing Date:

(Int'l) October 20, 2003

For:

PROCESSES FOR IDENTIFYING

**QUADRUPLEX-TARGETED ANTIVIRAL** 

**MOLECULES** 

Confirmation No.: 3896

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

# RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

MAIL STOP PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures mailed October 24, 2005, for which a response is set to expire December 24, 2005. Accordingly, this Response is timely filed.

Prior to examination of the above-identified application, the Examiner is respectfully requested to enter the following Sequence Listing, amendments, and remarks.

OCT 2 7 2005



#### United States Patent and Trademark Office

MORRISON&FOERSTER

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

Alexandria, Virginia 22313-1450

		1		
U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	A	TTY. DOCKET NO.	
10/531,545	Laurie L Hill-	532232000900		
	Adam SIDDIQUI - JAIN	INTERNATIONAL	APPLICATION NO.	
oroon RT		PCT/US03/33366		
25225 PSW MORRISON & FOERSTER LLP DOC	EKETED SOA DATA	I.A. FILING DATE	PRIORITY DATE	
2911 VALLEY CENTRE DRIVE	DATE: 12 24 65	10/20/2003	10/18/2002	
CAN DIECO CA 00400 0000	AL DUE DATE: 5/24/06	CONFIRMATION NO. 389		
		371 FORMALITIES *OC000000017306242*		

Date Mailed: 10/24/2005

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

cc: Gare Haney 11/15/05

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

#### JOHN L ANDERSON

Telephone: (703) 308-9140 EXT 211

### PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/531,545	PCT/US03/33366	532232000900

FORM PCT/DO/EO/922 (371 Formalities Notice)